ASCO 2005: Biology has spoken!;ASCO 2005: La biologie a parlé!

Bulletin du Cancer

Volumn 92, Issue 7-8, 2005, Pages 623-624

  Penault Llorca, Frédérique ^a   Bay, Jacques Olivier ^a  

^a CENTRE JEAN PERRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERLEUKIN 2; MEDROXYPROGESTERONE ACETATE; PACLITAXEL; SORAFENIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; METASTASIS; ONCOGENE NEU; TREATMENT OUTCOME; BREAST TUMOR; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; FEMALE; KIDNEY TUMOR; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; KIDNEY NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 24144436968     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (12)

1. Beuzeboc P, Scholl S, Garau XS, Vincent-Salomon A, Crémoux PD, Couturier J et al. Anticorps humanisé anti-HER2 (trastuzumab ou Herceptin): une avancée thérapeutique majeure dans le cancer du sein surexprimant cet oncogène? Bull Cancer 1999; 86: 544-9.
2. Penault-Llorca F, Cayre A. Statut actuel des tests HER2 dans les cancers du sein. Bull Cancer 2004; 91: S211-5.
3. Romond E. Joint analysis of NSABP-B-31 and NCCTG-N9831. http://www.asco.org/ac/1,1003,_12-002511-00_18-0034-00_19-005815-00_21-001,00. asp
4. Perez E. Further analysis of NCCTG-N9831. http://www.asco.org/ac/ 1,1003,_12-002511-00_18-0034-00_19-005817-00_21-001,00.asp
5. Piccart M. HERA trial, http://www.asco.org/ac/1,1003,_12-002511-00_18- 0034-00_19-005816-00_21-001,00.asp
6. Campone M, Bourbouloux E, Fumoleau P. Dysfonctionnements cardiaques induits par le trastuzumab. Bull Cancer 2004; 91: S166-73.
7. Négrier S, Perol D, Ravaud A, Chevreau C, Bay JO, Delva R et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized Percy Quattro trial. J Clin Oncol 2005; 23: 380s (abstract LBA4511).
8. Mutzer RJ, Rim BI, Michaelson MD, Redman BG, Hudes GR, Wilding G et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patinets with metastatic renal cell carcinoma (RCC). J Clin Oncol 2005; 23: 380s (abstract LBA4508).
9. Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan M et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2005; 23: 380s (abstract LBA4510).
10. Rini B, Rixe O, Bukowski R, Michaelson MD, Wilding G, Hudes G et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refraxctory, metastatic renal cell cancer (RCC). J Clin Oncol 2005; 23: 380s (abstract LBA4509).
11. Sledge GW. NC1/HERA Trials, http://www.asco.org/ac/1,1003,_12-002511- 00_18-0034-00_19-005813-00_21-001,00.asp
12. Maki RG, Fletcher JA, Heinrich MC, Morgan JA, George S, Desai J et al. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol 2005; 23: 818s (abstract 9011).